Warning letter
Phillips Co.: warning letter of May 8, 2017
FDA warning letter 512017 · Dallas District Office
Key facts
| Reference number | 512017 |
|---|---|
| Company | Phillips Co. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | May 8, 2017 |
| Posted date | May 16, 2017 |
| Issuing office | Dallas District Office |
| Product type | Drugs |
| CFR sections cited | 201.128, 211.34, 211.188, 211.22(d), 211.65(a), 211.84(d)(2), 211.100(a), 211.165(a) |
| Inspection city | Millerton |
| Inspection ZIP | 74750 |
| Inspection start date | Oct 4, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: